Cargando…

Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis

BACKGROUND: Moderate‐to‐severe atopic dermatitis (AD) is a chronic disease characterized by intense, persistent and debilitating itch, resulting in sleep deprivation, signs of anxiety and depression, impaired quality of life and reduced productivity. The Peak Pruritus Numerical Rating Scale (NRS) wa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yosipovitch, G., Reaney, M., Mastey, V., Eckert, L., Abbé, A., Nelson, L., Clark, M., Williams, N., Chen, Z., Ardeleanu, M., Akinlade, B., Graham, N.M.H., Pirozzi, G., Staudinger, H., Plaum, S., Radin, A., Gadkari, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850643/ https://www.ncbi.nlm.nih.gov/pubmed/30729499 http://dx.doi.org/10.1111/bjd.17744

Ejemplares similares

Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials
por: Beck, L.A., et al.
Publicado: (2020)

Neuroimmune interactions in chronic itch of atopic dermatitis
por: Yosipovitch, G., et al.
Publicado: (2019)

Current Clinical Options for the Management of Itch in Atopic Dermatitis
por: Lipman, Zoe M, et al.
Publicado: (2021)

Neuroimmune Mediators of Pruritus in Hispanic Scalp Psoriatic Itch
por: NATTKEMPER, Leigh A., et al.
Publicado: (2023)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019)

Development, Psychometric Validation and Responder Definition of Worst Itch Scale in Children with Severe Atopic Dermatitis
por: Paller, Amy S., et al.
Publicado: (2022)

Pruritus: an overview. What drives people to scratch an itch?
por: Lavery, Michael Joseph, et al.
Publicado: (2016)

Cowhage-Induced Itch as an Experimental Model for Pruritus. A Comparative Study with Histamine-Induced Itch
por: Papoiu, Alexandru D. P., et al.
Publicado: (2011)

Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
por: Silverberg, J.I., et al.
Publicado: (2019)

The Role of the Microbiome and Microbiome-Derived Metabolites in Atopic Dermatitis and Non-Histaminergic Itch
por: Li, Wei, et al.
Publicado: (2020)

Emerging Methods to Objectively Assess Pruritus in Atopic Dermatitis
por: Smith, Mary Patricia, et al.
Publicado: (2019)

Brain Processing of Contagious Itch in Patients with Atopic Dermatitis
por: Schut, Christina, et al.
Publicado: (2017)

Role of kappa‐opioid and mu‐opioid receptors in pruritus: Peripheral and central itch circuits
por: Kim, Brian S., et al.
Publicado: (2022)

How to measure itch in atopic dermatitis?
por: Oosterhaven, J.A.F.
Publicado: (2020)

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial
por: Worm, Margitta, et al.
Publicado: (2019)

A phase 2, open‐label study of single‐dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
por: Paller, A.S., et al.
Publicado: (2020)

Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
por: Kuznik, Andreas, et al.
Publicado: (2017)

Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL‐4Rα, in Atopic Dermatitis Patients and Normal Volunteers
por: Kovalenko, P, et al.
Publicado: (2016)

Itch in Atopic Dermatitis – What Is New?
por: Legat, Franz J.
Publicado: (2021)

Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis
por: Simpson, Eric, et al.
Publicado: (2019)

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
por: Wollenberg, A., et al.
Publicado: (2019)

Relationship Among Treatment, Pruritus, Investigator’s Static Global Assessment, and Quality of Life in Patients with Atopic Dermatitis
por: Simpson, Eric L., et al.
Publicado: (2021)

Intractable Itch in Atopic Dermatitis: Causes and Treatments
por: Umehara, Yoshie, et al.
Publicado: (2021)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Management of Itch in the Elderly: A Review
por: Fourzali, Kayla M., et al.
Publicado: (2019)

Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis
por: Eichenfield, Lawrence F., et al.
Publicado: (2019)

Effectiveness of a Multidisciplinary Itch Clinic in the Management of Chronic Pruritus
por: Michelle, Liang Weiting, et al.
Publicado: (2015)

Pruriplastic Itch—A Novel Pathogenic Concept in Chronic Pruritus
por: Misery, Laurent
Publicado: (2021)

Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis
por: Walsh, Carolyn M, et al.
Publicado: (2019)

Breaking the Itch–Scratch Cycle: Topical Options for the Management of Chronic Cutaneous Itch in Atopic Dermatitis
por: Harrison, Ian P., et al.
Publicado: (2019)

Itching in Atopic Dermatitis: Patient- and Physician-reported Outcomes in the German Atopic Dermatitis Registry TREATgermany
por: WEISSHAAR, Elke, et al.
Publicado: (2023)

Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial
por: Simpson, Eric L., et al.
Publicado: (2019)

Response to R. Waldman et al.: ‘Does IL‐4 inhibition play a role in dupilumab‐associated conjunctivitis?’
por: Ardeleanu, M., et al.
Publicado: (2020)

Comparison of itch characteristics and sleep in patients with brachioradial pruritus and notalgia paresthetica: A retrospective analysis from 2 itch centers
por: Lipman, Zoe M., et al.
Publicado: (2020)

A New Generation of Treatments for Itch
por: FOWLER, Emilie, et al.
Publicado: (2020)

Itch: from the skin to the brain – peripheral and central neural sensitization in chronic itch
por: Mahmoud, Omar, et al.
Publicado: (2023)

Neuroimmunological Mechanism of Pruritus in Atopic Dermatitis Focused on the Role of Serotonin
por: Kim, Kwangmi
Publicado: (2012)

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
por: Rerknimitr, Pawinee, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_cmcaenmocaaq6ckp7qt0oreqk3